RxDoctor Payments Data

Hung Nguyen, MD

Urology · Encinitas, CANPI 1023488806

Payments from drug & device makers

$12,218in general payments, 2019–2025

Across 307 payments — averaging $39.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Medtronic$1K
  • Coloplast$1K
  • Procept Biorobotics Corporation$763
  • Teleflex LLC$687
  • AbbVie$637
  • plus $5K from 48 others

What the payments were for

  • Consulting fees$1,0659%
  • Travel & lodging$2,61821%
  • Food & beverage$8,51070%
  • Education$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,218 in reported general payments places this provider in the 75th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$422,877
Medicare patients
688
Services billed
22,264

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron120$80,000
GemtesaVibegron34$37,064
Potassium Citrate ErPotassium Citrate47$8,058
Tamsulosin Hcl464$6,580
Methenamine Hippurate38$3,956
Testosterone15$3,506
Mirabegron ErMirabegron14$3,029
Estradiol59$3,018
Desmopressin Acetate11$1,354
Dutasteride15$1,210
Testosterone Cypionate17$1,181
Solifenacin Succinate29$1,104
Finasteride81$985
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst48$879
Betamethasone Dipropionate14$445

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$351$80,000120 claims
Sumitomo Pharma America, Inc.Gemtesa$87$37,06434 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,324 urology providers in California.

Other urology in Encinitas

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →